European Organisation For Research And Treatment Of Cancer - Eortc

This phase 2 trial studied 156 people with advanced EGFR-mutant lung cancer to find the best time to start the drug osimertinib. Some received it right away, while others started with a different drug and switched to osimertinib when a blood test showed a resistance marker. The s…

This study looks at whether a combination of a targeted drug (palbociclib) and standard hormone therapy can work as well as chemotherapy for older patients with a common type of early breast cancer. The goal is to prevent the cancer from coming back while avoiding the harsh side …

This study compares an experimental oral drug, darolutamide, to standard hormone therapy (injections) for men with prostate cancer that still responds to hormones. About 250 men with early-stage or limited metastatic disease will be randomly assigned to one of the two treatments.…

This study tests the drug nivolumab in 55 people with advanced thymoma or thymic carcinoma that has worsened after initial chemotherapy. The goal is to see if nivolumab can slow cancer growth and how safe it is. Participants receive nivolumab infusions, and researchers track tumo…

This phase 3 trial compares enzalutamide alone versus enzalutamide plus radium-223 (Ra223) in 446 men with castration-resistant prostate cancer that has spread to bones but causes few or no symptoms. The goal is to see if the combination delays cancer progression on scans. Partic…

This study gathers medical information and tumor samples from 200 men with breast cancer to help doctors learn more about the disease. It includes a look back at past cases (1990-2010) and a registry for new patients over 30 months. The goal is to understand how the disease behav…

This study looks at how gynecological cancer survivors feel and function after finishing their main treatment. About 1,100 women who are currently cancer-free will fill out questionnaires about their quality of life, anxiety, and sexual health. The goal is to learn what matters m…